55881-07-7

Basic information

• Product Name: Midecamycin Acetate
• Synonyms: Midecamycin Acetate;Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate;3'',9-Diacetylmydecamycin;9,3''-Di-O-acetylmidecamycin;Acecamycin;Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate (9CI);Miocamycin;Miokamycin
• CAS NO: 55881-07-7
• Molecular Formula: C₄₅H₇₁NO₁₇
• Molecular Weight: 898.046
• EINECS: 259-879-6
• Mol File: 55881-07-7.mol
• Article Data: 0

Chemical Properties

• Melting Point: ~220° (with coloration)
• Boiling Point: 878.7 °C at 760 mmHg
• Flash Point: 485.2 °C
• Appearance: White or offt-white crystalline powder
• Density: 1.2 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.524
• PKA: 13.06±0.70(Predicted)
• CAS DataBase Reference: Midecamycin Acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Midecamycin Acetate(55881-07-7)
• EPA Substance Registry System: Midecamycin Acetate(55881-07-7)

Safety Data

• Hazardous Substances Data: 55881-07-7(Hazardous Substances Data)

Usage

Description

Midecamycin Acetate, also known as Miokamycin, is a macrolide antibiotic derived from the Streptomyces genus of bacteria. It is characterized by its ability to target and treat a wide range of bacterial infections, particularly those caused by gram-positive bacteria and mycoplasma. Midecamycin Acetate functions by inhibiting bacterial protein synthesis, thereby disrupting the growth and reproduction of the bacteria.
Used in Pharmaceutical Industry:
Midecamycin Acetate is used as an antibiotic for the treatment of various types of bacterial infections, particularly those caused by gram-positive bacteria and mycoplasma. It is effective in treating respiratory tract infections, dermatological conditions, and surgical infections. The brand name for this antibiotic is MIOCAMYCIN.

Originator

Meiji Seika (Japan)

Pharmaceutical Applications

A semisynthetic diacetyl derivative of midecamycin A1. It is generally less active than erythromycin and some strains of H. influenzae and E. faecalis are resistant. It is rapidly and extensively metabolized, though some metabolites retain antibacterial activity.Absorption of the dry formulation is unaffected by food, whereas that of the oral suspension is delayed. In various studies the peak plasma concentration was 1.65, 1.31–3 and 1.3–2.7 mg/L after doses of 400, 600 and 800 mg, respectively.It is said to exhibit less toxicity than earlier macrolides. Attention has been paid to its interaction with theophylline, which resembles that of other macrolides. It is of limited availability.

InChI:InChI=1/C45H71NO17/c1-13-34(50)59-33-23-36(52)55-26(4)18-16-15-17-19-32(58-29(7)48)25(3)22-31(20-21-47)41(42(33)54-12)62-44-39(53)38(46(10)11)40(27(5)57-44)61-37-24-45(9,63-30(8)49)43(28(6)56-37)60-35(51)14-2/h15-17,19,21,25-28,31-33,37-44,53H,13-14,18,20,22-24H2,1-12H3/b16-15+,19-17+/t25-,26-,27-,28+,31-,32+,33-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1